This study is looking at a new way to screen for Type 1 Diabetes (T1D) called GTT@Home. This is a self-administered fingerstick test that you can do at home. Researchers want to see how accurate GTT@Home is compared to the standard in-clinic test. You might be able to join if you are between 8 and 45 years old, weigh at least 43 kg, and have at least one islet autoantibody (a marker in your blood that shows you're at risk for T1D). If you've been diagnosed with Stage 3 T1D within the last 100 days and are at least 12 years old, you may also be eligible. The main goal is to understand how well GTT@Home works. The current recruitment status is unclear.

Study design

This is an observational study with a planned enrollment of 60 participants. It will involve comparing a home-based test with a standard clinic test.

What's involved

You will complete one unsupervised GTT@Home test, a standard OGTT (oral glucose tolerance test) at a research facility, and a supervised GTT@Home. You will also have up to 10 days of blinded-CGM (continuous glucose monitoring) data collected.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, accuracy of GTT@Home, will be measured up to 4 weeks from enrollment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.